Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
the direct sale of 12,274 shares of common stock in multiple open-market transactions between March 17 and March 19, 2026, as disclosed in the SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value ~$839,000 Post-transaction common shares (direct) Post-transaction value (direct ownership) ~$2.34 million Transaction value based on SEC Form 4 weighted average purchase price ($68.36); post-transaction value based on trade-date close price as per SEC Form 4 filing. Key questions How does this sale compare to Whitfield's prior insider transactions at Tarsus Pharmaceuticals? The 12,274 shares sold exceeded the median insider sale of 9,835 shares over the past year, though it is in line with her recent pattern of reducing holdings in increments that reflect available share capacity. What proportion of her overall position did Whitfield reduce in this transaction? This sale represented 25.95% of her direct holdings at the time,
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus [Yahoo! Finance]Yahoo! Finance
- TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to TarsusGlobeNewswire
- Tarsus Pharmaceuticals (TARS) was upgraded by Lifesci Capital to "strong-buy".MarketBeat
- Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance [Yahoo! Finance]Yahoo! Finance
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/24/26 - Form 4
- 3/20/26 - Form 144
- 3/19/26 - Form 4
- TARS's page on the SEC website